头孢吡肟的临床药代动力学与药效学
头孢吡肟为第四代广谱头孢菌素,蛋白结合率低(20%),主要经肾排泄,约85%以原形从尿排出,消除半衰期2-2.3 h。综述总结其药代动力学/药效学及毒性动力学,指出重症、耐药菌感染等患者可能从治疗药物监测和延长/持续输注中获益,肾功能不全者需警惕神经毒性。
要点
- 头孢吡肟主要经肾排泄,约85%以原形从尿排出,半衰期2-2.3 h。
- 临床疗效目标暴露靶标为游离药物浓度超过最低抑菌浓度的时间占给药间隔70%。
- 重症、耐药菌感染患者可考虑治疗药物监测与延长/持续输注。
核心结论
- 头孢吡肟通常安全有效,临床疗效目标暴露靶标为70%时间内游离药物浓度超过最低抑菌浓度。
- 特定患者(如重症、危及生命感染或耐药病原体感染)可能从治疗药物监测中获益。
- 肾功能不全患者神经毒性报告增多,需关注其风险。
研究设计与样本
- 综述总结了头孢吡肟当代的药代动力学、药效学和毒性动力学。
主要发现
- 健康肾功能正常成人平均分布容积约0.2 L/kg,蛋白结合率相对较低(20%)。
- 约85%的剂量以原形从尿中排出,消除半衰期为2-2.3 h。
- 某些病理生理状态下头孢吡肟药代动力学改变,导致分布容积和清除率个体间变异大。
- 近年来,神经毒性报告增加,尤其在肾功能损害患者中。
关键数值与推荐
- 临床疗效目标暴露靶标为70%时间内游离药物浓度超过最低抑菌浓度。
临床怎么用
- 头孢吡肟可30-60 min输注或延长输注(3 h至持续给药)。
- 对重症、危及生命感染或耐药病原体感染患者,可考虑治疗药物监测。
- 肾功能不全患者需警惕神经毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against Gram-positive and Gram-negative pathogens. It is generally administered as an infusion over 30-60 min or as a prolonged infusion with infusion times from 3 h to continuous administration. Cefepime is widely distributed in biological fluids and tissues with an average volume of distribution of ~ 0.2 L/kg in healthy adults with normal renal function. Protein binding is relatively low (20%), and elimination is mainly renal. About 85% of the dose is excreted unchanged in the urine, with an elimination half-life of 2-2.3 h. The pharmacokinetics of cefepime is altered under certain pathophysiological conditions, resulting in high inter-individual variability in cefepime volume of distribution and clearance, which poses challenges for population dosing approaches. Consequently, therapeutic drug monitoring of cefepime may be beneficial in certain patients including those who are critically ill, have life-threatening infections, or are infected with more resistant pathogens. Cefepime is generally safe and efficacious, with a goal exposure target of 70% time of the free drug concentration over the minimum inhibitory concentration for clinical efficacy. In recent years, reports of neurotoxicity have increased, specifically in patients with impaired renal function. This review summarizes the pharmacokinetics, pharmacodynamics, and toxicodynamics of cefepime contemporarily in the setting of increasing cefepime exposures. We explore the potential benefits of extended or continuous infusions and therapeutic drug monitoring in special populations.
引用
- Pais GM, Chang J, Barreto EF, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022. PMID: 35764774. doi:10.1007/s40262-022-01137-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。